Eosinophils but not mast cells exert anti-tumorigenic activity, without being predictive markers of the long-term response to Bacillus Calmette-Guérin (BCG) therapy in patients with bladder carcinoma.
RNA-seq (gene expression) · human · 11 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Bladder cancerThis series is part of our curated briefing on it.
- Samples
- 11 samples: 11 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Eosinophils but not mast cells exert anti-tumorigenic activity, without being predictive markers of the long-term response to Bacillus Calmette-Guérin (BCG) therapy in patients with bladder carcinomaInflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE291192_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1232166 and SRA study SRP568124. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 11 sample titles: 11 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8830612 Sample #4- Tumor biopsy of responder patient to BCG treatment
- GSM8830613 Sample #6-Tumor biopsy of responder patient to BCG treatment
- GSM8830614 Sample #7-Tumor biopsy of non responder patient to BCG treatment
- GSM8830615 Sample #10- Tumor biopsy of responder patient to BCG treatment
- GSM8830616 Sample #15- Tumor biopsy of responder patient to BCG treatment
- GSM8830617 Sample #16- Tumor biopsy of non responder patient to BCG treatment
- GSM8830618 Sample #17- Tumor biopsy of non responder patient to BCG treatment
- GSM8830619 Sample #19- Tumor biopsy of non responder patient to BCG treatment
- GSM8830620 Sample #21- Tumor biopsy of responder patient to BCG treatment
- GSM8830621 Sample #28- Tumor biopsy of non responder patient to BCG treatment
- GSM8830622 Sample #29- Tumor biopsy of responder patient to BCG treatment
- GSE181389 Transcriptome profiling of HOXA13 and HOXB13 expression knockdown in bladder cancer cell lines. 59 samples same disease briefing
- GSE193755 Human bladder cancer cell line high throughput sequencing - genes regulated by hMSH2 12 samples same disease briefing
- GSE214886 Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer 12 samples same disease briefing
- GSE211924 UCHL5 promotes Tumorigenesis of Bladder Cancer by Activating AKT/mTOR signaling pathway and targeting c-myc, SLC25A19, and ICAM5. 9 samples same disease briefing
- GSE172359 Combination of urine exosomal mRNAs and lncRNAs as novel diagnostic biomarkers for bladder cancer 6 samples same disease briefing
- GSE182310 Transcriptome sequence of Human bladder cancer cell line 6 samples same disease briefing
- GSE193753 Human bladder cancer cell line high throughput sequencing - genes regulated by hMSH2 - CDDP therapy 6 samples same disease briefing
- GSE193754 Human bladder cancer cell line high throughput sequencing - genes regulated by hMSH2 - untreated 6 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.